Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer

Background Despite neoadjuvant chemoradiation (nCRT) followed by esophagectomy for locally advanced esophageal cancer, locoregional recurrence (LRR) is common and factors associated with LRR have not been clearly identified. Methods Patients were identified from a single institution, prospectively m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of surgical oncology 2018-02, Vol.117 (2), p.150-159
Hauptverfasser: Blackham, Aaron U., H. Naqvi, Syeda M., Schell, Michael J., Jin, William, Gangi, Alexandra, Almhanna, Khaldoun, Fontaine, Jacques P., Hoffe, Sarah E., Frakes, Jessica, Venkat, Puja, Pimiento, Jose M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Despite neoadjuvant chemoradiation (nCRT) followed by esophagectomy for locally advanced esophageal cancer, locoregional recurrence (LRR) is common and factors associated with LRR have not been clearly identified. Methods Patients were identified from a single institution, prospectively maintained database (1996‐2013). Patterns of recurrence were described and associated factors of LRR were analyzed using competing risks regression models. Results Of the 456 patients treated with nCRT and surgery, 167 patients developed recurrence. Locoregional and distant recurrences were observed in 69 (15.1%) and 140 (30.9%) patients, respectively. Time to recurrence (13.6 vs 10.4 months, P = 0.20) and median overall survival (29.3 vs 19.1 months, P = 0.12) were no different among the 27 patients (6%) who developed a solitary LRR compared to patients who developed distant recurrence. Univariable analysis identified lymphovascular invasion (HR 1.46, P = 0.07), lymph node ratio >0.5 (HR 2.16, P = 0.02), positive margin (HR 1.95, P = 0.05), lack of response to neoadjuvant therapy (HR 1.99, P 
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.24808